Emerging Markets Regulatory Tracker: Australia, Brazil, China, Russia (Vol. 1 No. 24)
This article was originally published in PharmAsia News
Executive Summary
The Emerging Markets Regulatory Tracker is a periodic PharmAsia News feature that summarizes and links to important regulatory developments impacting the biopharma and medical device industries in the Asia Pacific region and other emerging markets. The most recent issued appeared in PharmAsia News, Aug. 29, 2011. The Emerging Markets Regulatory Tracker is prepared for PharmAsia News by RegLink Associates LLC.
You may also be interested in...
Emerging Markets Regulatory Tracker: Brazil, China, Russia (Vol. 1 No. 25)
The Emerging Markets Regulatory Tracker is a periodic PharmAsia News feature that summarizes and links to important regulatory developments impacting the biopharma and medical device industries in the Asia Pacific region and other emerging markets. The most recent issued appeared in PharmAsia News, Sept. 5, 2011. The Emerging Markets Regulatory Tracker is prepared for PharmAsia News by RegLink Associates LLC.
Emerging Markets Regulatory Tracker: Brazil, China, Russia (Vol. 1 No. 25)
The Emerging Markets Regulatory Tracker is a periodic PharmAsia News feature that summarizes and links to important regulatory developments impacting the biopharma and medical device industries in the Asia Pacific region and other emerging markets. The most recent issued appeared in PharmAsia News, Sept. 5, 2011. The Emerging Markets Regulatory Tracker is prepared for PharmAsia News by RegLink Associates LLC.
China Broadens Scope Of Counterfeit Drugs For Criminal Prosecution, But Definition Still Murky
SHANGHAI - China recently broadened its criminal definition of counterfeit drugs to include all counterfeits, not just those that cause damage to human health. The revised Criminal Law opens more manufacturers of counterfeit drugs to criminal prosecution and makes prison terms mandatory for guilty parties